Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Slides:

Advertisements

Similar presentations

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

Advertisements

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

ATX-101 for reduction of submental fat: A phase III randomized controlled trial Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Volume 10, Issue 7, Pages (July 2018)

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

ATX-101 for reduction of submental fat: A phase III randomized controlled trial Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD,

Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades.

Lip edema Journal of the American Academy of Dermatology

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis.

Lawrence F. Eichenfield, MD, Lisa Beck, MD

Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study Kenji Kabashima, MD, PhD, Masutaka.

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis Eric L. Simpson, Shinichi Imafuku, Yves Poulin, Benjamin Ungar, Lisa Zhou,

A comparison of postprocedural wound care treatments: Do antibiotic-based ointments improve outcomes? Zoe D. Draelos, MD, FAAD, Ronald L. Rizer, PhD,

Medicaid acceptance among pediatric dermatologists

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Jennifer L. Hundley, MD, Christie L

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial Alice Gottlieb, MD, PhD, John Sullivan,

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled.

Tofacitinib therapy for children with severe alopecia areata

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

Postprocedural wound-healing efficacy following removal of dermatosis papulosa nigra lesions in an African American population: A comparison of a skin.

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Alan Menter, MD, Stephen K

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne Jerry Tan, MD, Diane Thiboutot, MD, Georg Popp,

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Anastasia O. Kurta, DO, Daisy Dai, PhD, Eric S

Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial Diane Thiboutot, MD, David.

Presentation transcript:

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial Eric L. Simpson, MD, Jane R. Parnes, MD, Dewei She, PhD, Sarah Crouch, BA (Hons), William Rees, PhD, May Mo, MS, René van der Merwe, MBChB Journal of the American Academy of Dermatology Volume 80, Issue 4, Pages 1013-1021 (April 2019) DOI: 10.1016/j.jaad.2018.11.059 Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Patient disposition. TCS, Topical corticosteroids. Journal of the American Academy of Dermatology 2019 80, 1013-1021DOI: (10.1016/j.jaad.2018.11.059) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 A, Percentage of patients who achieved EASI50, EASI75, and EASI90 responses at weeks 12 and 16. B, Percentage improvement from baseline in EASI (total score) over time. C, Percentage of patients with an IGA response at weeks 12 and 16. D, Percentage improvement from baseline in SCORAD (total score) over time. Analyses conducted in the ITT population. Patients were considered to be IGA responders if they had an IGA response of 0 or 1 and a reduction of ≥2 grades from baseline to week 12. IGA severity categories are 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), 4 (severe), and 5 (very severe). *Nominal P < .05 for the comparison with placebo. EASI50, A ≥50% reduction in Eczema Area and Severity Index score; EASI75, a ≥75% reduction in Eczema Area and Severity Index score; EASI90, a ≥90% reduction in Eczema Area and Severity Index score; IGA, Investigator's Global Assessment; ITT, intention-to-treat; SCORAD, Scoring of Atopic Dermatitis; SE, standard error; TCS, topical corticosteroids. Journal of the American Academy of Dermatology 2019 80, 1013-1021DOI: (10.1016/j.jaad.2018.11.059) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Percentage improvement from baseline in pruritus NRS for the ITT population. *Nominal P < .05 for the comparison with placebo. ITT, Intention-to-treat; NRS, numerical rating scale; SE, standard error; TCS, topical corticosteroids. Journal of the American Academy of Dermatology 2019 80, 1013-1021DOI: (10.1016/j.jaad.2018.11.059) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions